Back to search

Article

Complement C3 vs C5 inhibition in severe COVID-19: early clinical findings reveal differential biological efficacy

2020-08-21

Abstract excerpt

Growing clinical evidence has implicated complement as a pivotal driver of COVID-19 immunopathology. Deregulated complement activation may fuel cytokine-driven hyper-inflammation, thrombotic microangiopathy and NET-driven immunothrombosis, thereby leading to multi-organ failure. Complement therapeutics have gained traction as candidate drugs for countering the detrimental consequences of SARS-CoV-2 infection. Whet...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
9b7adfcf-543e-519d-917d-fb8ee5f7454b
DOI
10.1101/2020.08.17.20174474
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Complement C3 vs C5 inhibition in severe COVID-19: early clinical findings reveal differential biological efficacyDOI 10.1101/2020.08.17.20174474
Select a neighboring publication to make it the new centre.